The U.S. Food and Drug Administration has approved Edwards Lifesciences' SAPIEN 3 platform, a transcatheter aortic valve ...

Aortic stenosis is a narrowing of the aortic valve opening, which restricts blood flow from the heart to the rest of the body ...

New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a ...

The Society of Thoracic Surgeons (STS) today announced the launch of its latest surgical risk calculator designed for patients undergoing ascending aorta and aortic root surgery, with or without ...

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

And unlike mechanical valves ... In India, where Transcatheter Aortic Valve Replacement (TAVR) is gaining traction—especially with the market expected to grow at a CAGR of 24 percent till ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as the world’s first transfemoral transcatheter mitral valve replacement ...

Feb. 11, 2025 — Patients aged between 50 to 70 years with a mechanical heart valve replacement had better long-term survival compared to those with a biological valve, new research has ...

The company is looking to TMTT to support sales growth at a time when the larger transcatheter aortic valve replacement business has slowed. BTIG analysts are predicting TAVR sales will grow 3% in the ...

announced today that it received CE mark approval for its Sapien M3 mitral valve replacement system. Sapien M3 treats patients with symptomatic (moderate-to-severe or severe) mitral regurgitation ...

In this first-of-its-kind study, EPN increased rates of aortic valve replacement (AVR) for severe aortic stenosis ... focus cardiac ultrasound, mechanical circulatory support and pericardiocentesis.

These findings suggest a more liberal approach to ascending aortic surgery in patients with BAV undergoing valve replacement, but improved risk stratification is needed. There is a significant growth ...